A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä

Asymptomatic severe degenerative mitral regurgitation




TekijätBjörn, Rikhard; Strom, Jordan B.; Lloyd, Guy; Bhattacharyya, Sanjeev

KustantajaBMJ PUBLISHING GROUP

KustannuspaikkaLONDON

Julkaisuvuosi2025

JournalHeart

Tietokannassa oleva lehden nimiHEART

Lehden akronyymiHEART

Vuosikerta111

Numero2

Aloitussivu47

Lopetussivu54

Sivujen määrä8

ISSN1355-6037

eISSN1468-201X

DOIhttps://doi.org/10.1136/heartjnl-2024-324739

Verkko-osoitehttps://heart.bmj.com/content/111/2/47


Tiivistelmä
Degenerative mitral valve disease is common. Up to a quarter of patients with degenerative mitral valve disease may be asymptomatic despite having severe valve regurgitation. Current guideline indications for intervention in asymptomatic patient are centred on left ventricular dimensions and ejection fraction and may include consideration in atrial fibrillation, pulmonary hypertension and those with left atrial dilatation. However, despite intervention according to these recommendations, patients remain at risk of post-operative heart failure and mortality. Newer risk markers have been developed including left ventricular and atrial strain, myocardial fibrosis demonstrated using late gadolinium enhancement, mitral annular disjunction and ventricular arrhythmia burden. Translating newer markers into clinical practice will require integrating and identifying high-risk phenotypes that benefit from early intervention using machine learning techniques and artificial intelligence. Valve repair is the recommended intervention. However, repair rate and durability are dependent on both operator and centre volumes as well as valve characteristics. Recent advancements, including robotic surgery, may enhance repair rates; however, larger datasets are necessary to confirm these improvements. Efforts should focus on establishing high-volume regional centres of excellence for mitral valve repair.


Julkaisussa olevat rahoitustiedot
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.


Last updated on 2025-18-02 at 12:02